five

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

收藏
NIAID Data Ecosystem2026-03-11 收录
下载链接:
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2310049
下载链接
链接失效反馈
官方服务:
资源简介:
This is an interventional, randomized open-label, parallel-group, multicenter, dose escalation phase Ib/II study, to investigate the combination of Regorafenib and XELOX as 2nd line treatment in mCRC patients.
创建时间:
2019-07-15
二维码
社区交流群
二维码
科研交流群
商业服务